Year: 2024
Type: letter
Abstract: To the Editor: In their article on the ESCAPE-TRD trial, Reif et al. (Oct. 5 issue) 1 report on the efficacy and safety of esketamine nasal spray in comparison with extended-release quetiapine therapy in patients with treatment-resistant depression. The between-group differences in the change from baseline in the score on the Montgomery–Åsberg Depression Rating Scale (MADRS; scores range from 0 to 60, with higher scores indicating more severe depression) at 8 weeks (−2.8 points, favoring esketamine) and 32 weeks (−2.2 points, also favoring esketamine) were significant but were less than the minimum clinically important difference. 2 The data on remission that were . . .
Source: New England Journal of Medicine
DOI: 10.1056/nejmc2313230
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4390547870
